Resources
Explore our resources page, a hub of valuable content supporting our science and technology.
News
Articles, press releases, industry coverage and commentary.
Pluristyx Enables Safer, Universal Cell Therapy Solutions with Newly Issued U.S. Patent for iACT Stealth™ Technology
Seattle, WA – Pluristyx, the leading provider of innovative induced pluripotent
Pluristyx Announces Filing of Drug Master File for PluriBank™ iPSC Lines with U.S. FDA
Streamlined regulatory documentation accelerates development of next generation therapies Seattle,
Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCs
DURHAM, N.C. and SEATTLE, W.A., January 28, 2025 – Humacyte,
Pluristyx Announces Immediate Availability of GMP-Compliant PSXi013 iPSC Line for Advanced Therapy Development
SEATTLE, WA January 7, 2025 -- Pluristyx, a leading provider
Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs
SEATTLE, W.A., July 9, 2024 -- Pluristyx, a leading provider
Webinars & Videos
View our curated collection of webinars and videos.
The Next Big Thing in Pharma
Dr. Ben Fryer, Co-Founder and CEO of Pluristyx, talks to Pharma’s Almanac about pluripotent stem cells and how the company speeds up the R&D process by delivering Ready to Differentiate® cells.
panCELLa FailSafe®
MAKING CELL THERAPY SAFE: Cell therapies are largely derived from
A Failsafe® suicide gene-based system to improve safety & standardization of neural grafts (Parish)
Professor Clare Parish BBiomedSci, PhD; NHMRC Senior Research Fellow; Stem
Pluristyx Featured in Labroots Webinar
Dr. Ben Fryer, Co-Founder and CEO of Pluristyx, presented to webinar participants the “how and why” of integrating high quality ancillary raw materials into cell therapy product development and the manufacturing workflow, beginning with the starting cell source and MCB
Publications
Explore our comprehensive compilation of scientific publications.
Transplantation of Human Cortically-Specified Neuroepithelial Progenitor Cells Leads to Improved Functional Outcomes in a Mouse Model of Stroke.
Islam R, Drecun S, Varga BV, Vonderwalde I, Siu R, Nagy A and Morshead CM (2021) Front. Cell. Neurosci. 15:654290. doi:10.3389/fncel.2021.654290
Synaptic Dysfunction in Human Neurons With Autism-Associated Deletions in PTCHD1-AS
Ross PJ, Zhang WB, Mok RSF, Zaslavsky K, Deneault E, D’Abate L, Rodrigues DC, Yuen RKC, Faheem M, Mufteev M, Piekna A, Wei W, Pasceri P, Landa RJ, Nagy A, Varga
Initial cell maturity changes following transplantation in a hyaluronan-based hydrogel and impacts therapeutic success in the stroke-injured rodent brain.
Payne SL, Tuladhar A, Obermeyer JM, Varga BV, Teal CJ, Morshead CM, Nagy A, Shoichet MS (2019). Biomaterials. 2019 Feb;192:309-322. doi:10.1016/j.biomaterials.2018.11.020. Epub 2018 Nov 15. PMID: 30468998
Blog
Pluristyx blog articles and further resources to assist with your iPSC-based cell therapy development.
Cryopreservation (II): Cutting edge solutions
Introduction to Cryopreservation Cryopreservation, involving the preservation of cells and
FailSafe®: Engineered safety for tomorrow’s cell therapies
Chimeric antigen receptor (CAR) T-cell therapies are a novel class
Cryopreservation
Introduction to Cryopreservation Cryopreservation describes the controlled process of freezing